Tag: Letairis

The Food and Drug Administration (FDA) first approved the brand-name medication Letairis in 2007 for the treatment of pulmonary arterial hypertension (PAH). Since the patent expired, the active ingredient is now available as a generic version, making the generic for Letairis, which is ambrisentan, a more affordable option for many patients.

Without insurance, the brand-name medication Letairis can cost upwards of $13,000 for a single 30-day supply. The high price for this pulmonary hypertension drug makes understanding how much does Letairis cost and finding financial assistance options crucial for patients.

According to the Pulmonary Hypertension Association, treatments for the rare and serious condition of pulmonary arterial hypertension (PAH) often involve medications that have a unique distribution and handling process. Among these is Letairis (ambrisentan), and for those asking, 'Is Letairis a specialty drug?', the answer is definitively yes. The classification is due to its specialized nature, high cost, and the strict safety monitoring required by the FDA.

Pulmonary arterial hypertension (PAH) is a chronic, progressive disease characterized by elevated blood pressure in the arteries of the lungs. Approved by the FDA in 2007, LETAIRIS, also known by its active ingredient ambrisentan, offers a targeted approach to managing this serious condition. But **what does LETAIRIS do** to alleviate the symptoms and slow the progression of PAH?